Janssen’s Sarich: Randomized Controlled Trials, Real-World Evidence Go Best Together
Executive Summary
Janssen’s Troy Sarich outlines why it’s hard to emulate randomized controlled trials with real-world evidence studies, emphasizing that the two are “not in competition.” He also highlights the huge strides made by AI-driven technology firms to provide “research-ready” structured data and new game-changing advances in the area of health sensors.
You may also be interested in...
Moderna CCO Highlights Panomics, Pre-emptive Care As Pharma’s Future
Moderna’s CCO Corinne Le Goff highlighted panomics and pre-emptive care as the industry’s future at a recent event, even as she saw on-shoring and “regaining sovereignty” over health expenditure as being essential to medicines security.
Digital Acceleration And ‘Broken’ Customer Experience: What Pharma Should Look Out For
Biopharma experts discuss at a summit core issues around ensuring that fast-paced digital acceleration does not jeopardize the overall experience of healthcare professionals. Clarity about customer needs/behaviors, embracing a fail-fast, learn-fast mindset and measuring customer experience were among the aspects touched upon.
Real-World Evidence Under Consideration For Use In Interchangeable Biosimilars Applications
US FDA research funded under BSUFA III will investigate what kind of safety data is needed for interchangeability. A demonstration project aimed at improving biosimilar product development efficiency and enhanced regulatory decision-making also will be part of the new regulatory science research program.